Behavior After Inclusion and Clearance of Neisseria gonorrhoeae RNA and DNA
| Characteristic . | Total . | Urethra . | Rectum . | Endocervix . | P Value . |
|---|---|---|---|---|---|
| Behavior after inclusion | |||||
| No. of samples collected, median (range) | 27 (20–28) | 28 (25–28) | 28 (20–28) | 27 (20–28) | .01 |
| Patients with missed samples | 36 (58) | 8 (40) | 10 (48) | 18 (86) | .006 |
| Rectal/vaginal douching | 11 (26) | … | 7 (33) | 4 (19) | .29 |
| Sexual contact | 40 (65) | 14 (70) | 12 (57) | 14 (67) | .67 |
| Unprotected sex | 17 (27) | 4 (20) | 5 (24) | 8 (38) | .39 |
| RNA clearancea | |||||
| Patients in the analysisb | 61 | 19 (31) | 21 (34) | 21 (34) | |
| Clearance during follow-up | 61 (100) | 19 (100) | 21 (100) | 21 (100) | |
| Reinfection after clearance | 1 (2) | 0 (0) | 0 (0) | 1 (5) | .63 |
| Day of clearance definablec | 56 (92) | 17 (89) | 21 (100) | 18 (86) | .26 |
| Time to clearance, d, median (range) | 2 (1–7) | 2 (1–5) | 2 (1–6) | 3 (1–7) | .04 |
| RNA blipsd | |||||
| Samples at risk for blip | 1308 | 438 | 468 | 402 | |
| No. of blips | 11 | 0 | 8 | 3 | |
| No. of patients | 6 (10) | 0 (0) | 4 (19) | 2 (10) | .15 |
| Time to first blip, d, median (range) | 7 (3–23) | … | 7.5 (3–23) | 6 (3–9) | .48 |
| RLU value, mean (range)e | 220.6 (91–463) | … | 241.1 (116–463) | 195.9 (91–407) | .48 |
| DNA clearancea | |||||
| Patients in the analysisf | 61 | 20 (33) | 20 (33) | 21 (34) | |
| Clearance during follow-up | 61 (100) | 20 (100) | 20 (100) | 21 (100) | |
| Reinfection after clearance | 1 (2) | 0 (0) | 0 (0) | 1 (5) | 1.00 |
| Day of clearance definablec | 59 (97) | 19 (95) | 20 (100) | 20 (95) | 1.00 |
| Time to clearance, d, median (range) | 2 (1–15) | 3 (1–15) | 2 (1–4) | 3.5 (1–8) | <.001 |
| DNA blipsd | |||||
| Samples at risk for blip | 1285 | 422 | 461 | 402 | |
| No. of blips | 19 | 5 | 10 | 4 | |
| No. of patients | 10 (16) | 2 (10) | 5 (25) | 3 (14) | .48 |
| Time to first blip, d, median (range) | 4.5 (1–9) | 2 (1–3) | 5 (2–9) | 6 (3–6) | .23 |
| Ct value, mean (range) | 37.9 (35.4–39.5) | 38.5 (38.0–39.3) | 37.5 (35.7–39.5) | 38.0 (35.4–39.3) | .54 |
| Characteristic . | Total . | Urethra . | Rectum . | Endocervix . | P Value . |
|---|---|---|---|---|---|
| Behavior after inclusion | |||||
| No. of samples collected, median (range) | 27 (20–28) | 28 (25–28) | 28 (20–28) | 27 (20–28) | .01 |
| Patients with missed samples | 36 (58) | 8 (40) | 10 (48) | 18 (86) | .006 |
| Rectal/vaginal douching | 11 (26) | … | 7 (33) | 4 (19) | .29 |
| Sexual contact | 40 (65) | 14 (70) | 12 (57) | 14 (67) | .67 |
| Unprotected sex | 17 (27) | 4 (20) | 5 (24) | 8 (38) | .39 |
| RNA clearancea | |||||
| Patients in the analysisb | 61 | 19 (31) | 21 (34) | 21 (34) | |
| Clearance during follow-up | 61 (100) | 19 (100) | 21 (100) | 21 (100) | |
| Reinfection after clearance | 1 (2) | 0 (0) | 0 (0) | 1 (5) | .63 |
| Day of clearance definablec | 56 (92) | 17 (89) | 21 (100) | 18 (86) | .26 |
| Time to clearance, d, median (range) | 2 (1–7) | 2 (1–5) | 2 (1–6) | 3 (1–7) | .04 |
| RNA blipsd | |||||
| Samples at risk for blip | 1308 | 438 | 468 | 402 | |
| No. of blips | 11 | 0 | 8 | 3 | |
| No. of patients | 6 (10) | 0 (0) | 4 (19) | 2 (10) | .15 |
| Time to first blip, d, median (range) | 7 (3–23) | … | 7.5 (3–23) | 6 (3–9) | .48 |
| RLU value, mean (range)e | 220.6 (91–463) | … | 241.1 (116–463) | 195.9 (91–407) | .48 |
| DNA clearancea | |||||
| Patients in the analysisf | 61 | 20 (33) | 20 (33) | 21 (34) | |
| Clearance during follow-up | 61 (100) | 20 (100) | 20 (100) | 21 (100) | |
| Reinfection after clearance | 1 (2) | 0 (0) | 0 (0) | 1 (5) | 1.00 |
| Day of clearance definablec | 59 (97) | 19 (95) | 20 (100) | 20 (95) | 1.00 |
| Time to clearance, d, median (range) | 2 (1–15) | 3 (1–15) | 2 (1–4) | 3.5 (1–8) | <.001 |
| DNA blipsd | |||||
| Samples at risk for blip | 1285 | 422 | 461 | 402 | |
| No. of blips | 19 | 5 | 10 | 4 | |
| No. of patients | 10 (16) | 2 (10) | 5 (25) | 3 (14) | .48 |
| Time to first blip, d, median (range) | 4.5 (1–9) | 2 (1–3) | 5 (2–9) | 6 (3–6) | .23 |
| Ct value, mean (range) | 37.9 (35.4–39.5) | 38.5 (38.0–39.3) | 37.5 (35.7–39.5) | 38.0 (35.4–39.3) | .54 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: Ct, cycle threshold; RLU, relative light unit.
a Based on a definition of 3 consecutive negative tests following a positive test.
b One of 62 patients was excluded due to negative results for Neisseria gonorrhoeae, Chlamydia trachomatis, and human DNA (β-globin) in the first sample after treatment.
c The exact day of clearance could not be defined due to missing samples in the period of clearance.
d Blip was defined as a positive test following clearance. Samples from all patients were included; for those without an exact day of clearance due to missing samples, all samples after the first 3 consecutive negative results were considered at risk for blips.
e Including samples positive for N. gonorrhoeae only (n = 7).
f One of 62 patients was excluded due to a negative pretreatment result for N. gonorrhoeae DNA.
Behavior After Inclusion and Clearance of Neisseria gonorrhoeae RNA and DNA
| Characteristic . | Total . | Urethra . | Rectum . | Endocervix . | P Value . |
|---|---|---|---|---|---|
| Behavior after inclusion | |||||
| No. of samples collected, median (range) | 27 (20–28) | 28 (25–28) | 28 (20–28) | 27 (20–28) | .01 |
| Patients with missed samples | 36 (58) | 8 (40) | 10 (48) | 18 (86) | .006 |
| Rectal/vaginal douching | 11 (26) | … | 7 (33) | 4 (19) | .29 |
| Sexual contact | 40 (65) | 14 (70) | 12 (57) | 14 (67) | .67 |
| Unprotected sex | 17 (27) | 4 (20) | 5 (24) | 8 (38) | .39 |
| RNA clearancea | |||||
| Patients in the analysisb | 61 | 19 (31) | 21 (34) | 21 (34) | |
| Clearance during follow-up | 61 (100) | 19 (100) | 21 (100) | 21 (100) | |
| Reinfection after clearance | 1 (2) | 0 (0) | 0 (0) | 1 (5) | .63 |
| Day of clearance definablec | 56 (92) | 17 (89) | 21 (100) | 18 (86) | .26 |
| Time to clearance, d, median (range) | 2 (1–7) | 2 (1–5) | 2 (1–6) | 3 (1–7) | .04 |
| RNA blipsd | |||||
| Samples at risk for blip | 1308 | 438 | 468 | 402 | |
| No. of blips | 11 | 0 | 8 | 3 | |
| No. of patients | 6 (10) | 0 (0) | 4 (19) | 2 (10) | .15 |
| Time to first blip, d, median (range) | 7 (3–23) | … | 7.5 (3–23) | 6 (3–9) | .48 |
| RLU value, mean (range)e | 220.6 (91–463) | … | 241.1 (116–463) | 195.9 (91–407) | .48 |
| DNA clearancea | |||||
| Patients in the analysisf | 61 | 20 (33) | 20 (33) | 21 (34) | |
| Clearance during follow-up | 61 (100) | 20 (100) | 20 (100) | 21 (100) | |
| Reinfection after clearance | 1 (2) | 0 (0) | 0 (0) | 1 (5) | 1.00 |
| Day of clearance definablec | 59 (97) | 19 (95) | 20 (100) | 20 (95) | 1.00 |
| Time to clearance, d, median (range) | 2 (1–15) | 3 (1–15) | 2 (1–4) | 3.5 (1–8) | <.001 |
| DNA blipsd | |||||
| Samples at risk for blip | 1285 | 422 | 461 | 402 | |
| No. of blips | 19 | 5 | 10 | 4 | |
| No. of patients | 10 (16) | 2 (10) | 5 (25) | 3 (14) | .48 |
| Time to first blip, d, median (range) | 4.5 (1–9) | 2 (1–3) | 5 (2–9) | 6 (3–6) | .23 |
| Ct value, mean (range) | 37.9 (35.4–39.5) | 38.5 (38.0–39.3) | 37.5 (35.7–39.5) | 38.0 (35.4–39.3) | .54 |
| Characteristic . | Total . | Urethra . | Rectum . | Endocervix . | P Value . |
|---|---|---|---|---|---|
| Behavior after inclusion | |||||
| No. of samples collected, median (range) | 27 (20–28) | 28 (25–28) | 28 (20–28) | 27 (20–28) | .01 |
| Patients with missed samples | 36 (58) | 8 (40) | 10 (48) | 18 (86) | .006 |
| Rectal/vaginal douching | 11 (26) | … | 7 (33) | 4 (19) | .29 |
| Sexual contact | 40 (65) | 14 (70) | 12 (57) | 14 (67) | .67 |
| Unprotected sex | 17 (27) | 4 (20) | 5 (24) | 8 (38) | .39 |
| RNA clearancea | |||||
| Patients in the analysisb | 61 | 19 (31) | 21 (34) | 21 (34) | |
| Clearance during follow-up | 61 (100) | 19 (100) | 21 (100) | 21 (100) | |
| Reinfection after clearance | 1 (2) | 0 (0) | 0 (0) | 1 (5) | .63 |
| Day of clearance definablec | 56 (92) | 17 (89) | 21 (100) | 18 (86) | .26 |
| Time to clearance, d, median (range) | 2 (1–7) | 2 (1–5) | 2 (1–6) | 3 (1–7) | .04 |
| RNA blipsd | |||||
| Samples at risk for blip | 1308 | 438 | 468 | 402 | |
| No. of blips | 11 | 0 | 8 | 3 | |
| No. of patients | 6 (10) | 0 (0) | 4 (19) | 2 (10) | .15 |
| Time to first blip, d, median (range) | 7 (3–23) | … | 7.5 (3–23) | 6 (3–9) | .48 |
| RLU value, mean (range)e | 220.6 (91–463) | … | 241.1 (116–463) | 195.9 (91–407) | .48 |
| DNA clearancea | |||||
| Patients in the analysisf | 61 | 20 (33) | 20 (33) | 21 (34) | |
| Clearance during follow-up | 61 (100) | 20 (100) | 20 (100) | 21 (100) | |
| Reinfection after clearance | 1 (2) | 0 (0) | 0 (0) | 1 (5) | 1.00 |
| Day of clearance definablec | 59 (97) | 19 (95) | 20 (100) | 20 (95) | 1.00 |
| Time to clearance, d, median (range) | 2 (1–15) | 3 (1–15) | 2 (1–4) | 3.5 (1–8) | <.001 |
| DNA blipsd | |||||
| Samples at risk for blip | 1285 | 422 | 461 | 402 | |
| No. of blips | 19 | 5 | 10 | 4 | |
| No. of patients | 10 (16) | 2 (10) | 5 (25) | 3 (14) | .48 |
| Time to first blip, d, median (range) | 4.5 (1–9) | 2 (1–3) | 5 (2–9) | 6 (3–6) | .23 |
| Ct value, mean (range) | 37.9 (35.4–39.5) | 38.5 (38.0–39.3) | 37.5 (35.7–39.5) | 38.0 (35.4–39.3) | .54 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: Ct, cycle threshold; RLU, relative light unit.
a Based on a definition of 3 consecutive negative tests following a positive test.
b One of 62 patients was excluded due to negative results for Neisseria gonorrhoeae, Chlamydia trachomatis, and human DNA (β-globin) in the first sample after treatment.
c The exact day of clearance could not be defined due to missing samples in the period of clearance.
d Blip was defined as a positive test following clearance. Samples from all patients were included; for those without an exact day of clearance due to missing samples, all samples after the first 3 consecutive negative results were considered at risk for blips.
e Including samples positive for N. gonorrhoeae only (n = 7).
f One of 62 patients was excluded due to a negative pretreatment result for N. gonorrhoeae DNA.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
